-DOCSTART-	O

Title	O
:	O
Switching	O
patients	B-P
with	I-P
asthma	I-P
from	O
chlorofluorocarbon	B-I
(	I-I
CFC	I-I
)	I-I
albuterol	I-I
to	O
hydrofluoroalkane	B-I
-	I-I
134a	I-I
(	I-I
HFA	I-I
)	I-I
albuterol	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
asthma	I-P
stabilized	O
on	O
CFC	B-I
albuterol	I-I
during	O
a	O
12	O
-	O
week	O
safety	B-O
and	O
efficacy	B-O
trial	O
were	O
randomized	O
to	O
either	O
continue	O
receiving	O
CFC	B-I
albuterol	I-I
or	O
to	O
be	O
switched	O
to	O
receive	O
HFA	B-I
albuterol	I-I
in	O
a	O
yearlong	O
safety	B-O
and	O
efficacy	B-O
trial	O
.	O

Safety	B-O
and	O
efficacy	B-O
were	O
compared	O
over	O
the	O
first	O
12	O
weeks	O
of	O
the	O
yearlong	O
trial	O
between	O
patients	O
who	O
had	O
remained	O
on	O
CFC	B-I
albuterol	I-I
and	O
those	O
who	O
had	O
been	O
switched	O
to	O
HFA	B-I
albuterol	I-I
.	O

Bronchodilator	B-O
efficacy	I-O
was	O
evaluated	O
by	O
serial	B-O
spirometry	I-O
for	O
6	O
hr	O
after	O
the	O
patients	O
self	O
-	O
administered	O
the	O
study	O
drug	O
in	O
the	O
clinic	O
.	O

Safety	B-O
was	O
assessed	O
by	O
measuring	O
changes	O
in	O
pulse	B-O
rate	I-O
,	O
blood	B-O
pressure	I-O
,	O
and	O
electrocardiogram	B-O
(	I-O
ECG	I-O
)	I-O
intervals	O
after	O
dosing	O
with	O
study	O
drug	O
,	O
monitoring	O
adverse	B-O
events	I-O
,	O
and	O
performing	O
prestudy	O
and	O
poststudy	O
laboratory	B-O
testing	I-O
and	O
physical	B-O
examinations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Behavioral	O
and	O
physiological	O
effects	O
of	O
remifentanil	B-I
and	O
alfentanil	B-I
in	O
healthy	B-P
volunteers	I-P
.	O

METHODS	O
:	O
Ten	B-P
healthy	I-P
volunteers	I-P
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
trial	O
in	O
which	O
they	O
received	O
an	B-C
infusion	I-C
of	I-C
saline	I-C
,	O
remifentanil	B-I
,	O
or	O
alfentanil	B-I
for	O
120	O
min	O
.	O

The	O
age	O
-	O
and	O
weight	O
-	O
adjusted	O
infusions	O
(	O
determined	O
with	O
STANPUMP	O
,	O
a	O
computer	O
modeling	O
software	O
package	O
)	O
were	O
given	O
to	O
achieve	O
three	O
predicted	O
constant	O
plasma	O
levels	O
for	O
40	B-I
min	I-I
each	I-I
of	I-I
remifentanil	I-I
(	O
0	O
.	O
75	O
,	O
1	O
.	O
5	O
,	O
and	O
3	O
ng	O
/	O
ml	O
)	O
and	O
alfentanil	B-I
(	O
16	O
,	O
32	O
,	O
and	O
64	O
ng	O
/	O
ml	O
)	O
.	O

Mood	B-O
forms	I-O
and	O
psychomotor	B-O
tests	I-O
were	O
completed	O
,	O
and	O
miosis	B-O
was	O
assessed	O
,	O
during	O
and	O
after	O
the	O
infusions	O
.	O

In	O
addition	O
,	O
analgesia	B-O
was	O
tested	O
at	O
each	O
dose	O
level	O
using	O
a	B-O
cold	I-O
-	I-O
pressor	I-O
test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Genotyping	O
of	O
CYP21	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
sex	O
-	O
specific	O
gene	O
in	O
neonatal	O
screening	O
for	O
congenital	O
adrenal	O
hyperplasia	O
.	O

METHODS	O
:	O
Blood	B-I
-	I-I
impregnated	I-I
filter	I-I
papers	I-I
(	I-I
Guthrie	I-I
cards	I-I
)	I-I
from	O
603	O
randomly	O
chosen	O
New	O
Zealand	O
neonates	O
were	O
genotyped	O
blind	O
to	O
17	O
-	O
hydroxyprogesterone	O
(	O
17	O
-	O
OHP	O
)	O
levels	O
.	O

Another	O
50	O
samples	O
from	O
Swiss	O
and	O
North	O
American	O
infants	O
with	O
correlative	O
hormonal	O
data	O
were	O
also	O
genotyped	O
.	O

DNA	B-O
was	O
extracted	O
,	O
and	O
gene	B-O
-	I-O
specific	I-O
PCR	I-O
was	O
performed	O
.	O

CYP21	B-O
PCR	I-O
products	I-O
were	O
subjected	O
to	O
ligase	B-O
detection	I-O
reaction	I-O
,	O
simultaneously	O
analyzing	O
9	B-O
CYP21	I-O
mutations	I-O
;	O
PCR	B-O
products	I-O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	B-O
gel	I-O
analysis	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Piperacillin	B-I
/	O
tazobactam	B-I
plus	O
tobramycin	B-I
versus	O
ceftazidime	B-C
plus	O
tobramycin	B-C
as	O
empiric	O
therapy	O
for	O
fever	O
in	O
severely	B-P
neutropenic	I-P
patients	I-P
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
center	O
study	O
,	O
patients	B-P
who	I-P
experienced	I-P
a	I-P
total	I-P
of	I-P
247	I-P
febrile	I-P
episodes	I-P
were	O
prospectively	O
randomized	O
to	O
receive	O
either	O
our	O
standard	B-C
regimen	I-C
,	O
ceftazidime	B-C
3	O
g	O
/	O
day	O
(	O
1	O
g	O
t	O
.	O
i	O
.	O
d	O
.	O
)	O
plus	O
tobramycin	B-C
3	O
mg	O
/	O
kg	O
per	O
day	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
,	O
or	O
piperacillin	B-I
12	O
g	O
/	O
day	O
plus	O
tazobactam	B-I
1	O
.	O
5	O
g	O
/	O
day	O
(	O
4	O
g	O
+	O
0	O
.	O
5	O
g	O
t	O
.	O
i	O
.	O
d	O
.	O
)	O
plus	O
tobramycin	B-I
3	O
mg	O
/	O
kg	O
per	O
day	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
.	O

Vancomycin	O
was	O
added	O
in	O
all	O
cases	O
of	O
persistent	O
fever	O
in	O
the	O
ceftazidime	O
arm	O
,	O
but	O
only	O
when	O
there	O
was	O
microbiologically	O
documented	O
resistance	O
in	O
the	O
piperacillin	O
/	O
tazobactam	O
arm	O
.	O

-DOCSTART-	O

Title	O
:	O
Independent	O
prognostic	O
information	O
provided	O
by	O
sphygmomanometrically	B-I
determined	I-I
pulse	I-I
pressure	I-I
and	O
mean	B-I
arterial	I-I
pressure	I-I
in	O
patients	B-P
with	I-P
left	I-P
ventricular	I-P
dysfunction	I-P
.	O

METHODS	O
:	O
Pulse	B-I
and	O
mean	B-I
arterial	I-I
pressure	I-I
were	O
analyzed	O
for	O
their	O
effect	O
on	O
mortality	B-O
,	O
adjusting	O
for	O
other	O
modifiers	O
of	O
risk	O
,	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
analysis	O
of	O
data	O
collected	O
from	O
6	B-P
,	I-P
781	I-P
patients	I-P
randomized	I-P
into	I-P
the	I-P
Studies	I-P
of	I-P
Left	I-P
Ventricular	I-P
Dysfunction	I-P
trials	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Rett	O
syndrome	O
:	O
randomized	O
controlled	O
trial	O
of	O
L	B-I
-	I-I
carnitine	I-I
.	O

METHODS	O
:	O
To	O
investigate	O
whether	O
L	B-I
-	I-I
carnitine	I-I
might	O
be	O
of	O
benefit	O
in	O
Rett	O
syndrome	O
,	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
trial	O
of	O
L	B-I
-	I-I
carnitine	I-I
has	O
been	O
completed	O
in	O
35	B-P
subjects	I-P
.	O

Eight	O
-	O
week	O
treatment	O
phases	O
were	O
completed	O
for	O
both	O
a	B-C
placebo	I-C
and	O
L	B-I
-	I-I
carnitine	I-I
.	O

Outcome	O
was	O
measured	O
by	O
parents	O
/	O
caregivers	O
and	O
at	O
medical	O
follow	O
-	O
up	O
using	O
three	O
established	O
tools	O
:	O
the	B-O
Rett	I-O
Syndrome	I-O
Motor	I-O
Behavioral	I-O
Assessment	I-O
,	O
the	B-O
Hand	I-O
Apraxia	I-O
Scale	I-O
,	O
and	O
the	B-O
Patient	I-O
Well	I-O
-	I-O
Being	I-O
Index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Naltrexone	B-I
and	O
communication	O
skills	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
children	I-P
with	I-P
autism	I-P
,	I-P
3	I-P
.	I-P
0	I-P
to	I-P
8	I-P
.	I-P
3	I-P
years	I-P
old	I-P
(	I-P
mean	I-P
5	I-P
.	I-P
1	I-P
)	I-P
who	I-P
were	I-P
living	I-P
at	I-P
home	I-P
and	I-P
attending	I-P
appropriate	I-P
school	I-P
programs	I-P
,	O
participated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
trial	O
.	O

Naltrexone	B-I
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
or	O
placebo	B-C
was	O
administered	O
daily	O
for	O
2	O
weeks	O
.	O

Communication	B-O
was	O
evaluated	O
from	O
videotaped	O
samples	O
of	O
seminaturalistic	O
parent	O
-	O
child	O
interaction	O
.	O

Child	B-O
and	O
parent	B-O
language	I-O
were	O
assessed	O
using	O
similar	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
term	O
response	O
to	O
therapy	O
of	O
chronic	O
anti	O
-	O
HBe	O
-	O
positive	O
hepatitis	O
B	O
is	O
poor	O
independent	O
of	O
type	O
and	O
schedule	O
of	O
interferon	O
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
two	I-P
consecutive	I-P
anti	I-P
-	I-P
HBe	I-P
-	I-P
positive	I-P
chronic	I-P
hepatitis	I-P
B	I-P
patients	I-P
(	I-P
59	I-P
male	I-P
and	I-P
13	I-P
female	I-P
,	I-P
median	I-P
age	I-P
41	I-P
yr	I-P
)	I-P
stratified	I-P
by	I-P
sex	I-P
and	I-P
histology	I-P
were	O
randomly	O
allocated	O
to	O
three	O
treatment	O
arms	O
.	O

Twenty	O
-	O
seven	O
patients	O
(	O
A	O
)	O
received	O
10	B-I
million	I-I
units	I-I
alpha	I-I
-	I-I
N1	I-I
IFN	I-I
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
24	O
wk	O
(	O
total	O
dose	O
:	O
720	O
million	O
units	O
)	O
;	O
21	O
(	O
B	O
)	O
received	O
9	B-I
million	I-I
units	I-I
alpha	I-I
-	I-I
2a	I-I
IFN	I-I
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
4	O
wk	O
,	O
followed	O
by	O
18	O
million	O
units	O
for	O
12	O
wk	O
and	O
9	O
million	O
units	O
for	O
8	O
wk	O
(	O
972	O
million	O
units	O
)	O
;	O
24	O
(	O
C	O
)	O
received	O
2	B-I
alpha	I-I
-	I-I
2a	I-I
IFN	I-I
courses	I-I
(	O
9	O
million	O
units	O
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
16	O
and	O
12	O
wk	O
separated	O
by	O
a	O
6	O
-	O
month	O
interval	O
[	O
756	O
million	O
units	O
]	O
)	O
.	O

Primary	O
response	O
was	O
defined	O
by	O
normal	B-O
ALT	I-O
and	O
serum	B-O
HBV	I-O
-	I-O
DNA	I-O
levels	I-O
below	I-O
10	I-O
pg	I-O
/	I-O
ml	I-O
at	O
the	O
end	O
of	O
therapy	O
and	O
sustained	B-O
response	I-O
by	I-O
normal	I-O
ALT	I-O
(	O
tested	O
monthly	O
)	O
,	O
undetectable	B-O
HBV	I-O
-	I-O
DNA	I-O
and	O
IgM	B-O
anti	I-O
-	I-O
HBc	I-O
(	O
<	O
7	O
I	O
.	O
U	O
.	O

Paul	O
Ehrlich	O
Institute	O
)	O
(	O
tested	O
every	O
3	O
months	O
)	O
during	O
the	O
posttreatment	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjuvant	B-I
L	I-I
-	I-I
arginine	I-I
treatment	O
for	O
in	O
-	O
vitro	O
fertilization	O
in	O
poor	O
responder	O
patients	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
34	I-P
patients	I-P
undergoing	I-P
assisted	I-P
reproduction	I-P
was	O
divided	O
in	O
two	O
groups	O
according	O
to	O
different	B-I
ovarian	I-I
stimulation	I-I
protocols	I-I
:	O
(	O
i	O
)	O
flare	B-I
-	I-I
up	I-I
gonadotrophin	I-I
-	I-I
releasing	I-I
hormone	I-I
analogue	I-I
(	I-I
GnRHa	I-I
)	I-I
plus	O
elevated	B-I
pure	I-I
follicle	I-I
stimulating	I-I
hormone	I-I
(	I-I
pFSH	I-I
)	I-I
(	O
n	O
=	O
17	O
)	O
;	O
and	O
(	O
ii	O
)	O
flare	B-I
-	I-I
up	I-I
GnRHa	I-I
plus	O
elevated	B-I
pFSH	I-I
plus	O
oral	B-I
L	I-I
-	I-I
arginine	I-I
(	O
n	O
=	O
17	O
)	O
.	O

During	O
the	B-I
ovarian	I-I
stimulation	I-I
regimen	I-I
,	O
the	O
patients	O
were	O
submitted	O
to	O
hormonal	B-O
(	O
oestradiol	B-O
and	O
growth	B-O
hormone	I-O
)	O
,	O
ultrasonographic	B-O
(	O
follicular	B-O
number	I-O
and	O
diameter	B-O
,	O
endometrial	B-O
thickness	I-O
)	O
and	O
Doppler	B-O
(	O
uterine	B-O
and	O
perifollicular	B-O
arteries	I-O
)	O
evaluations	O
.	O

Furthermore	O
,	O
the	B-O
plasma	I-O
and	O
follicular	B-O
fluid	I-O
concentrations	I-O
of	O
arginine	B-O
,	O
citrulline	B-O
,	O
nitrite	B-O
/	O
nitrate	B-O
(	B-O
NO2	I-O
-	I-O
/	O
NO3	B-O
-	I-O
)	I-O
,	O
and	O
insulin	B-O
-	I-O
like	I-O
growth	I-O
factor	I-O
-	I-O
1	I-O
(	I-O
IGF	I-O
-	I-O
1	I-O
)	I-O
were	O
assayed	O
.	O

-DOCSTART-	O

Title	O
:	O
Delineation	O
of	O
cryptogenic	O
Lennox	O
-	O
Gastaut	O
syndrome	O
and	O
myoclonic	O
astatic	O
epilepsy	O
using	O
multiple	B-I
correspondence	I-I
analysis	I-I
.	O

METHODS	O
:	O
We	O
applied	O
MCA	B-I
to	O
a	O
series	O
of	O
72	B-P
children	I-P
with	I-P
no	I-P
evidence	I-P
of	I-P
brain	I-P
damage	I-P
,	I-P
starting	I-P
epilepsy	I-P
between	I-P
1	I-P
and	I-P
10	I-P
years	I-P
,	I-P
with	I-P
two	I-P
or	I-P
more	I-P
types	I-P
of	I-P
generalised	I-P
seizures	I-P
.	O

We	O
excluded	O
patients	O
with	O
infantile	O
spasms	O
or	O
typical	O
absences	O
.	O

MCA	B-I
was	O
performed	O
on	O
all	B-O
clinical	I-O
and	O
EEG	B-O
parameters	I-O
,	O
first	O
throughout	O
follow	O
-	O
up	O
,	O
then	O
restricted	O
to	O
the	O
first	O
year	O
of	O
the	O
disease	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessment	O
of	O
the	O
pain	O
of	O
blood	B-I
-	I-I
sugar	I-I
testing	I-I
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
the	B-I
oral	I-I
neuraminidase	I-I
inhibitor	I-I
oseltamivir	I-I
in	O
experimental	O
human	O
influenza	O
:	O
randomized	O
controlled	O
trials	O
for	O
prevention	O
and	O
treatment	O
.	O

METHODS	O
:	O
Two	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trials	O
conducted	O
between	O
June	O
and	O
July	O
1997	O
.	O

Individual	O
hotel	O
rooms	O
;	O
2	O
large	O
US	O
university	O
medical	O
schools	O
.	O

A	B-P
total	I-P
of	I-P
117	I-P
healthy	I-P
adult	I-P
volunteers	I-P
(	I-P
aged	I-P
18	I-P
-	I-P
40	I-P
years	I-P
;	I-P
median	I-P
age	I-P
,	I-P
21	I-P
years	I-P
)	I-P
who	I-P
were	I-P
susceptible	I-P
(	I-P
hemagglutination	I-P
-	I-P
inhibition	I-P
antibody	I-P
titer	I-P
<	I-P
or	I-P
=1	I-P
:	I-P
8	I-P
)	I-P
.	O

All	O
subjects	O
were	O
inoculated	O
intranasally	O
with	O
influenza	O
A	O
/	O
Texas	O
/	O
36	O
/	O
91	O
(	O
H1N1	O
)	O
virus	O
.	O

For	O
the	O
prophylaxis	O
study	O
,	O
oral	B-I
oseltamivir	I-I
(	O
100	O
mg	O
once	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
100	O
mg	O
twice	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
or	O
matching	B-C
placebo	I-C
[	O
n	O
=	O
13	O
]	O
,	O
starting	O
26	O
hours	O
before	O
virus	O
inoculation	O
)	O
was	O
administered	O
.	O

For	O
the	O
treatment	O
study	O
,	O
the	O
same	O
drug	O
was	O
given	O
(	O
20	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
twice	O
daily	O
,	O
200	O
mg	O
once	O
daily	O
,	O
or	O
matching	B-C
placebo	I-C
[	O
n	O
=	O
16	O
]	O
,	O
in	O
each	O
group	O
starting	O
28	O
hours	O
after	O
inoculation	O
)	O
.	O

All	O
regimens	O
were	O
continued	O
for	O
5	O
days	O
.	O

Comparing	O
placebo	B-C
groups	O
with	O
pooled	O
treatment	O
groups	O
,	O
for	O
prophylaxis	O
,	O
outcomes	O
included	O
frequency	B-O
of	I-O
infection	I-O
and	O
viral	B-O
shedding	I-O
;	O
for	O
treatment	O
,	O
viral	B-O
shedding	I-O
in	I-O
titers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Cholesterol	O
-	O
lowering	O
effect	O
of	O
stanol	B-I
ester	I-I
in	O
a	B-P
US	I-P
population	I-P
of	I-P
mildly	I-P
hypercholesterolemic	I-P
men	I-P
and	I-P
women	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
After	O
a	O
run	O
-	O
in	O
phase	O
,	O
318	B-P
subjects	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
following	O
margarine	B-I
-	I-I
like	I-I
spreads	I-I
containing	I-I
stanol	I-I
ester	I-I
or	O
placebo	B-C
for	O
8	O
weeks	O
:	O
EU	O
3	O
G	O
:	O
1	B-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
European	O
formula	O
3	O
times	O
a	O
day	O
;	O
US	O
3	O
G	O
:	O
1	B-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
US	O
2	O
G	O
:	O
0	B-I
.	I-I
67	I-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
or	O
placebo	B-C
spread	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Randomised	O
controlled	O
trial	O
of	O
patient	O
triggered	B-I
and	O
conventional	B-C
fast	I-C
rate	I-C
ventilation	I-C
in	O
neonatal	O
respiratory	O
distress	O
syndrome	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
and	I-P
eighty	I-P
six	I-P
preterm	I-P
infants	I-P
with	I-P
birthweights	I-P
from	I-P
1000	I-P
to	I-P
2000	I-P
g	I-P
,	I-P
and	I-P
requiring	I-P
ventilation	I-P
for	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
within	I-P
24	I-P
hours	I-P
of	I-P
birth	I-P
,	O
were	O
randomised	O
to	O
receive	O
either	O
conventional	B-C
or	O
trigger	B-I
ventilation	I-I
with	O
the	B-I
SLE	I-I
2000	I-I
ventilator	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
stentless	B-I
versus	O
conventional	B-C
aortic	I-C
valve	I-C
replacement	I-C
.	O

METHODS	O
:	O
Stentless	B-I
(	O
Freestyle	O
,	O
Toronto	O
,	O
n	O
=	O
106	O
)	O
or	O
conventional	B-C
biological	I-C
aortic	I-C
valves	I-C
(	O
Carpentier	O
-	O
Edwards	O
,	O
n	O
=	O
74	O
)	O
were	O
evaluated	O
prospectively	O
.	O

-DOCSTART-	O

Title	O
:	O
Computer	B-I
-	I-I
assisted	I-I
instruction	I-I
:	O
an	O
effective	O
instructional	O
method	O
for	O
HIV	O
prevention	O
education	O
?	O
.	O

METHODS	O
:	O
Students	B-P
enrolled	I-P
in	I-P
a	I-P
Human	I-P
Sexuality	I-P
course	I-P
(	I-P
N	I-P
=	I-P
152	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
CAI	B-I
,	O
Lecture	B-I
,	O
or	O
No	B-C
Intervention	I-C
group	O
.	O

Participants	O
in	O
the	B-I
CAI	I-I
group	O
reviewed	O
a	B-I
1	I-I
-	I-I
hour	I-I
long	I-I
CAI	I-I
program	I-I
,	O
participants	O
in	O
the	B-I
Lecture	I-I
group	O
were	O
presented	O
with	O
a	O
1	B-I
-	I-I
hour	I-I
long	I-I
lecture	I-I
,	O
and	O
participants	O
in	O
the	B-C
No	I-C
Intervention	I-C
group	O
received	O
no	O
intervention	O
.	O

After	O
completing	O
the	O
respective	O
interventions	O
,	O
all	O
participants	O
completed	O
the	B-O
HIV	I-O
questionnaire	I-O
,	O
which	O
measured	O
selected	B-O
Social	I-O
Cognitive	I-O
Theory	I-O
constructs	I-O
associated	I-O
with	I-O
HIV	I-O
preventive	I-O
behaviors	I-O
.	O

MANCOVA	O
,	O
ANCOVA	O
and	O
Post	O
Hoc	O
analyses	O
were	O
utilized	O
to	O
test	O
for	O
significant	O
differences	O
among	O
the	O
three	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Photodynamic	B-I
therapy	I-I
with	I-I
5	I-I
-	I-I
aminolaevulinic	I-I
acid	I-I
or	O
placebo	B-C
for	O
recalcitrant	O
foot	O
and	O
hand	O
warts	O
:	O
randomised	O
double	O
-	O
blind	O
trial	O
.	O

METHODS	O
:	O
Recalcitrant	O
foot	O
and	O
hand	O
warts	O
were	O
randomly	O
assigned	O
to	O
six	O
repetitive	O
ALA	B-I
-	I-I
PDT	I-I
or	O
placebo	B-C
-	I-C
PDT	I-C
interventions	O
combined	O
with	O
standard	O
treatment	O
encompassing	O
paring	O
followed	O
by	O
a	O
keratolytic	O
(	O
Verucid	O
)	O
.	O

Standardised	B-O
photographs	I-O
of	I-O
each	I-O
wart	I-O
were	O
taken	O
before	O
,	O
during	O
(	O
week	O
7	O
)	O
and	O
after	O
treatment	O
(	O
weeks	O
14	O
and	O
18	O
)	O
.	O

The	B-O
area	I-O
of	I-O
each	I-O
wart	I-O
compared	I-O
with	I-O
entry	I-O
area	I-O
was	O
the	O
primary	O
outcome	O
variable	O
,	O
measured	O
from	O
photographs	B-O
by	O
an	O
evaluator	O
unaware	O
of	O
treatment	O
allocation	O
for	O
intervention	O
.	O

Pain	B-O
intensity	I-O
immediately	O
and	O
24	O
h	O
after	O
each	O
intervention	O
was	O
assessed	O
by	O
a	B-O
five	I-O
-	I-O
point	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Language	O
,	O
speech	O
sound	O
production	O
,	O
and	O
cognition	O
in	O
three	B-P
-	I-P
year	I-P
-	I-P
old	I-P
children	I-P
in	I-P
relation	I-P
to	I-P
otitis	I-P
media	I-P
in	I-P
their	I-P
first	I-P
three	I-P
years	I-P
of	I-P
life	I-P
.	O

METHODS	O
:	O
We	O
enrolled	O
6350	B-P
healthy	I-P
infants	I-P
by	I-P
2	I-P
months	I-P
of	I-P
age	I-P
who	I-P
presented	I-P
for	I-P
primary	I-P
care	I-P
at	I-P
1	I-P
of	I-P
2	I-P
urban	I-P
hospitals	I-P
or	I-P
1	I-P
of	I-P
2	I-P
small	I-P
town	I-P
/	I-P
rural	I-P
and	I-P
4	I-P
suburban	I-P
private	I-P
pediatric	I-P
practices	I-P
.	O

We	O
intensively	O
monitored	O
the	O
children	O
'	O
s	O
middle	O
ear	O
status	O
by	O
pneumatic	O
otoscopy	O
,	O
supplemented	O
by	O
tympanometry	O
,	O
throughout	O
their	O
first	O
3	O
years	O
of	O
life	O
;	O
we	O
monitored	O
the	O
validity	O
of	O
the	O
otoscopic	O
observations	O
on	O
an	O
ongoing	O
basis	O
;	O
and	O
we	O
treated	O
children	O
for	O
otitis	O
media	O
according	O
to	O
specified	O
guidelines	O
.	O

Children	O
who	O
met	O
specified	O
minimum	O
criteria	O
regarding	O
the	O
persistence	O
of	O
MEE	O
became	O
eligible	O
for	O
a	O
clinical	O
trial	O
in	O
which	O
they	O
were	O
assigned	O
randomly	O
to	O
undergo	O
tympanostomy	B-I
tube	I-I
placement	I-I
either	I-I
promptly	I-I
or	O
after	B-I
a	I-I
defined	I-I
extended	I-I
period	I-I
if	I-I
MEE	I-I
remained	I-I
present	I-I
.	O

From	O
among	O
those	O
remaining	O
,	O
we	O
selected	O
randomly	O
,	O
within	O
sociodemographic	O
strata	O
,	O
a	B-P
sample	I-P
of	I-P
241	I-P
children	I-P
who	I-P
represented	I-P
a	I-P
spectrum	I-P
of	I-P
MEE	I-P
experience	I-P
from	O
having	O
no	O
MEE	O
to	O
having	O
MEE	O
whose	O
cumulative	O
duration	O
fell	O
just	O
short	O
of	O
meeting	O
randomization	O
criteria	O
.	O

In	O
subjects	O
so	O
selected	O
,	O
the	O
estimated	O
duration	O
of	O
MEE	O
ranged	O
from	O
none	O
to	O
65	O
.	O
6	O
%	O
of	O
the	O
first	O
year	O
of	O
life	O
and	O
44	O
.	O
8	O
%	O
of	O
the	O
first	O
3	O
years	O
of	O
life	O
.	O

In	O
these	O
241	B-P
children	I-P
we	O
assessed	O
language	B-O
development	I-O
,	O
speech	B-O
sound	I-O
production	I-O
,	O
and	O
cognition	B-O
at	I-O
3	I-O
years	I-O
of	I-O
age	I-O
,	O
using	O
both	O
formal	B-O
tests	I-O
and	O
conversational	B-O
samples	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Does	O
waiting	B-I
matter	O
?	O
A	O
randomized	O
controlled	O
trial	O
of	O
new	B-I
non	I-I
-	I-I
urgent	I-I
rheumatology	I-I
out	I-I
-	I-I
patient	I-I
referrals	I-I
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
randomized	O
controlled	O
clinical	O
study	O
evaluating	O
a	B-I
'	I-I
fast	I-I
track	I-I
'	I-I
appointment	I-I
with	O
a	O
6	O
-	O
week	O
target	O
waiting	O
time	O
against	O
an	B-C
'	I-C
ordinary	I-C
'	I-C
appointment	I-C
in	O
the	O
main	O
city	O
out	O
-	O
patient	O
clinic	O
of	O
the	O
rheumatology	O
service	O
for	O
the	O
Lothian	O
and	O
Borders	O
region	O
(	O
population	O
approximately	O
1	O
million	O
)	O
.	O

Health	B-O
status	I-O
was	O
measured	O
using	O
the	B-O
SF12	I-O
physical	I-O
and	O
mental	B-O
summary	I-O
component	I-O
T	B-O
-	I-O
scores	I-O
and	O
pain	B-O
was	O
measured	O
with	O
a	B-O
100	I-O
mm	I-O
visual	I-O
analogue	I-O
pain	I-O
scale	I-O
.	O

Secondary	O
outcomes	O
were	O
health	B-O
utility	I-O
and	O
perceived	B-O
health	I-O
both	O
measured	O
with	O
the	B-O
EuroQol	I-O
instrument	I-O
,	O
mental	B-O
health	I-O
measured	O
with	O
the	B-O
Hospital	I-O
Anxiety	I-O
and	I-O
Depression	I-O
scale	I-O
,	O
disability	B-O
with	O
the	B-O
modified	I-O
Health	I-O
Assessment	I-O
Questionnaire	I-O
and	O
economic	B-O
costs	I-O
measured	O
from	O
a	B-O
societal	I-O
perspective	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Epirubicin	B-I
-	I-I
based	I-I
chemotherapy	I-I
in	O
metastatic	B-P
breast	I-P
cancer	I-P
patients	I-P
:	O
role	O
of	O
dose	O
-	O
intensity	O
and	O
duration	O
of	O
treatment	O
.	O

METHODS	O
:	O
Four	B-P
hundred	I-P
seventeen	I-P
anthracycline	I-P
-	I-P
naive	I-P
MBC	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
following	O
regimens	O
:	O
arm	O
A	O
:	O
11	B-I
cycles	I-I
of	I-I
fluorouracil	I-I
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-I
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
cyclophosphamide	B-I
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
FEC	O
75	O
)	O
every	O
21	O
days	O
;	O
arm	O
B	O
:	O
four	B-I
cycles	I-I
of	I-I
FEC	I-I
100	I-I
(	O
same	O
regimen	O
but	O
with	O
epirubicin	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
then	O
eight	B-I
cycles	I-I
of	I-I
FEC	I-I
50	I-I
(	O
epirubicin	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
;	O
and	O
arm	O
C	O
:	O
four	B-I
cycles	I-I
of	I-I
FEC	I-I
100	I-I
then	O
restart	O
the	O
same	O
regimen	O
at	O
disease	O
progression	O
in	O
case	O
of	O
prior	O
response	O
or	O
stabilization	O
.	O

-DOCSTART-	O

Title	O
:	O
Beta	B-I
radiation	I-I
as	O
an	O
adjunct	O
to	O
low	O
-	O
risk	O
trabeculectomy	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomized	O
trial	O
of	O
65	B-P
eyes	I-P
was	O
designed	O
,	O
with	O
31	O
eyes	O
receiving	O
750	B-I
rads	I-I
of	I-I
intraoperative	I-I
beta	I-I
radiation	I-I
(	O
group	O
1	O
)	O
,	O
and	O
34	O
eyes	O
receiving	O
no	B-C
supplementation	I-C
(	O
group	O
2	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Short	O
-	O
and	O
long	O
-	O
term	O
results	O
after	O
thrombolytic	B-I
treatment	I-I
of	O
deep	O
venous	O
thrombosis	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
250	I-P
patients	I-P
averaging	I-P
40	I-P
years	I-P
of	I-P
age	I-P
with	I-P
acute	I-P
DVT	I-P
were	O
randomized	O
into	O
five	O
groups	O
to	O
receive	O
full	O
heparinization	O
(	O
1	O
,	O
000	O
IU	O
/	O
h	O
)	O
and	O
compression	O
treatment	O
,	O
with	O
four	O
groups	O
also	O
administered	O
locoregional	B-I
tissue	I-I
plasminogen	I-I
activator	I-I
(	O
20	O
mg	O
/	O
day	O
)	O
or	O
urokinase	B-I
(	O
100	O
,	O
000	O
IU	O
/	O
day	O
)	O
or	O
systemic	B-I
streptokinase	I-I
(	O
3	O
,	O
000	O
,	O
000	O
IU	O
daily	O
)	O
or	O
urokinase	B-I
(	O
5	O
,	O
000	O
,	O
000	O
IU	O
daily	O
)	O
.	O

All	O
groups	O
then	O
received	O
anticoagulation	O
and	O
compression	O
treatment	O
for	O
one	O
year	O
.	O

Primary	O
efficacy	O
criteria	O
included	O
the	O
change	O
after	O
one	O
year	O
in	O
the	B-O
number	I-O
of	I-O
closed	I-O
vein	I-O
segments	I-O
and	O
the	B-O
occurrence	I-O
of	I-O
postthrombotic	I-O
syndrome	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
New	B-I
therapeutic	I-I
approaches	I-I
in	O
irritable	O
bowel	O
syndrome	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Complication	O
rate	O
after	O
gastrectomy	B-I
and	I-I
pouch	I-I
reconstruction	I-I
with	I-I
Longmire	I-I
interposition	I-I
]	O
.	O

METHODS	O
:	O
49	O
patients	O
who	O
underwent	O
gastrectomy	B-I
with	I-I
Longmire	I-I
-	I-I
Interposition	I-I
with	I-I
(	O
n	O
=	O
33	O
)	O
or	O
without	B-I
(	I-I
n	I-I
=	I-I
16	I-I
)	I-I
an	I-I
additional	I-I
pouch	I-I
and	O
46	O
patients	O
with	O
a	B-I
Roux	I-I
-	I-I
en	I-I
-	I-I
Y	I-I
-	I-I
reconstruction	I-I
were	O
analysed	O
retrospectively	O
.	O

Complication	B-O
rate	I-O
and	O
mortality	B-O
were	O
studied	O
.	O

-DOCSTART-	O

Title	O
:	O
Perioperative	B-I
blood	I-I
transfusions	I-I
,	I-I
with	I-I
or	O
without	B-I
allogeneic	I-I
leucocytes	I-I
,	O
relate	O
to	O
survival	O
,	O
not	O
to	O
cancer	O
recurrence	O
.	O

METHODS	O
:	O
Packed	B-I
red	I-I
cells	I-I
without	I-I
buffy	I-I
coat	I-I
(	O
PC	B-I
group	O
)	O
were	O
compared	O
with	O
filtered	B-I
,	I-I
leucoreduced	I-I
,	I-I
red	I-I
cells	I-I
(	O
LD	B-I
group	O
)	O
in	O
a	O
randomized	O
trial	O
of	O
697	B-P
patients	I-P
with	I-P
colorectal	I-P
carcinoma	I-P
.	O

Five	B-O
-	I-O
year	I-O
survival	I-O
and	O
cancer	B-O
recurrence	I-O
rates	I-O
were	O
determined	O
,	O
with	O
special	O
emphasis	O
on	O
the	B-O
location	I-O
of	I-O
recurrence	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Phase	O
-	O
dependent	O
modulation	O
of	O
the	B-I
soleus	I-I
H	I-I
-	I-I
reflex	I-I
during	O
rhythmical	O
arm	O
swing	O
in	O
humans	O
.	O

-DOCSTART-	O

Title	O
:	O
Interferential	B-I
therapy	I-I
electrode	I-I
placement	I-I
technique	I-I
in	O
acute	O
low	O
back	O
pain	O
:	O
a	O
preliminary	O
investigation	O
.	O

METHODS	O
:	O
Single	O
-	O
blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
with	O
a	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

Outpatient	O
physiotherapy	O
departments	O
in	O
hospital	O
and	O
university	O
settings	O
.	O

A	B-P
random	I-P
sample	I-P
of	I-P
60	I-P
eligible	I-P
patients	I-P
with	I-P
back	I-P
pain	I-P
(	I-P
28	I-P
men	I-P
,	I-P
32	I-P
women	I-P
)	I-P
were	O
recruited	O
by	O
general	O
practitioners	O
and	O
self	O
-	O
referral	O
for	O
physiotherapy	O
treatment	O
and	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
.	O

(	O
1	O
)	O
"	O
IFT	B-I
painful	I-I
area	I-I
"	O
and	O
The	B-I
Back	I-I
Book	I-I
,	O
(	O
2	O
)	O
"	O
IFT	B-I
spinal	I-I
nerve	I-I
"	O
and	O
The	B-I
Back	I-I
Book	I-I
,	O
and	O
(	O
3	O
)	O
"	O
Control	O
,	O
"	O
The	B-C
Back	I-C
Book	I-C
only	I-C
.	O

Standardized	O
IFT	O
stimulation	O
parameters	O
were	O
used	O
:	O
carrier	O
frequency	O
3	O
.	O
85	O
kHz	O
;	O
140	O
Hz	O
constant	O
;	O
pulse	O
duration	O
130	O
micros	O
;	O
30	O
minutes	O
'	O
duration	O
.	O

Pain	B-O
Rating	I-O
Index	I-O
,	O
Roland	B-O
-	I-O
Morris	I-O
Disability	I-O
Questionnaire	I-O
(	I-O
RMDQ	I-O
)	I-O
,	O
and	O
EuroQol	B-O
were	O
completed	O
by	O
subjects	O
pretreatment	O
,	O
at	O
discharge	O
,	O
and	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
evaluation	O
of	O
calcium	B-I
hydroxide	I-I
and	O
zinc	B-I
oxide	I-I
eugenol	I-I
as	O
root	O
canal	O
filling	O
materials	O
for	O
primary	O
molars	O
:	O
a	O
clinical	O
and	O
radiographic	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
assessing	O
the	O
health	O
economics	O
of	O
realtime	B-I
teledermatology	I-I
compared	O
with	O
conventional	B-C
care	I-C
:	O
an	O
urban	O
versus	O
rural	O
perspective	O
.	O

METHODS	O
:	O
One	O
urban	O
and	O
one	O
rural	O
health	O
centre	O
were	O
linked	O
to	O
a	O
regional	O
hospital	O
in	O
Northern	O
Ireland	O
by	O
ISDN	O
at	O
128	O
kbit	O
/	O
s	O
.	O

Over	O
two	O
years	O
,	O
274	B-P
patients	I-P
required	I-P
a	I-P
hospital	I-P
outpatient	I-P
dermatology	I-P
referral	I-P
-	I-P
-	I-P
126	I-P
patients	I-P
(	I-P
46	I-P
%	I-P
)	I-P
were	O
randomized	O
to	O
a	B-I
telemedicine	I-I
consultation	I-I
and	O
148	O
(	O
54	O
%	O
)	O
to	O
a	B-C
conventional	I-C
hospital	I-C
outpatient	I-C
consultation	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
and	O
microbial	O
evaluation	O
of	O
a	B-I
histatin	I-I
-	I-I
containing	I-I
mouthrinse	I-I
in	O
humans	B-P
with	I-P
experimental	I-P
gingivitis	I-P
.	O

METHODS	O
:	O
159	B-P
periodontally	I-P
healthy	I-P
subjects	I-P
abstained	O
from	O
oral	O
hygiene	O
procedures	O
and	O
self	O
-	O
administered	O
either	O
0	B-I
.	I-I
005	I-I
%	I-I
,	O
0	B-I
.	I-I
01	I-I
%	I-I
,	O
0	B-I
.	I-I
05	I-I
%	I-I
P	I-I
-	I-I
113	I-I
or	O
placebo	B-C
mouthrinse	I-C
formulations	I-C
twice	O
daily	O
over	O
a	O
four	O
week	O
treatment	O
period	O
.	O

During	O
this	O
time	O
,	O
the	B-O
safety	I-O
,	O
anti	B-O
-	I-O
plaque	I-O
,	O
and	O
anti	B-O
-	I-O
gingivitis	I-O
effects	I-O
of	I-O
P	I-O
-	I-O
113	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
L	B-I
-	I-I
arginine	I-I
and	O
S	B-I
-	I-I
nitrosoglutathione	I-I
reduce	O
embolization	O
in	O
humans	O
.	O

-DOCSTART-	O

Title	O
:	O
"	O
Confirmatory	O
"	O
trials	O
:	O
symptom	O
reduction	O
as	O
efficacy	O
measure	O
.	O

-DOCSTART-	O

Title	O
:	O
Immune	O
reconstitution	O
after	O
allogeneic	B-I
marrow	I-I
transplantation	I-I
compared	O
with	O
blood	B-I
stem	I-I
cell	I-I
transplantation	I-I
.	O

METHODS	O
:	O
Immune	B-O
reconstitution	I-O
was	O
studied	O
in	O
115	B-P
patients	I-P
randomly	O
assigned	O
to	O
receive	O
either	O
allogeneic	B-I
marrow	I-I
or	O
filgrastim	B-I
-	I-I
mobilized	I-I
blood	I-I
stem	I-I
cell	I-I
transplantation	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
tolerability	O
of	O
antibiotics	B-I
in	O
patients	B-P
undergoing	I-P
H	I-P
.	I-P
pylori	I-P
eradication	I-P
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
ninety	I-P
-	I-P
three	I-P
(	I-P
193	I-P
)	I-P
H	I-P
.	I-P
pylori	I-P
-	I-P
positive	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
7	O
-	O
day	O
treatments	O
:	O
Group	O
A	O
(	O
N	O
=	O
64	O
)	O
:	O
amoxicillin	B-I
,	O
clarithromycin	B-I
and	O
rabeprazole	B-I
;	O
Group	O
B	O
(	O
N	O
=	O
64	O
)	O
:	O
tinidazole	B-I
,	O
clarithromycin	B-I
and	O
ranitidine	B-I
bismuth	I-I
citrate	I-I
;	O
Group	O
C	O
(	O
N	O
=	O
65	O
)	O
:	O
tinidazole	B-I
,	O
clarithromycin	B-I
and	O
rabeprazole	B-I
Eradication	B-O
was	O
assessed	O
by	O
13C	B-O
-	I-O
Urea	I-O
Breath	I-O
Test	I-O
6	O
-	O
8	O
weeks	O
after	O
the	O
end	O
of	O
the	O
therapy	O
.	O

Not	O
-	O
eradicated	O
patients	O
underwent	O
a	O
second	O
cycle	O
with	O
tinidazole	B-I
,	O
tetracycline	B-I
,	O
bismuth	B-I
and	O
rabeprazole	B-I
.	O

All	O
patients	O
were	O
asked	O
to	O
complete	O
a	B-O
validated	I-O
questionnaire	I-O
regarding	O
presence	B-O
and	O
intensity	B-O
of	I-O
drug	I-O
side	I-O
effects	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rehabilitation	O
outcomes	O
following	O
percutaneous	B-I
coronary	I-I
interventions	I-I
(	I-I
PCI	I-I
)	I-I
.	O

METHODS	O
:	O
Data	B-O
were	O
collected	O
at	O
time	O
1	O
(	O
T	O
(	O
1	O
)	O
)	O
during	O
hospital	B-O
admission	I-O
,	O
time	O
2	O
(	O
T	O
(	O
2	O
)	O
)	O
approximately	O
2	O
months	O
post	O
-	O
PCI	B-I
,	O
and	O
time	O
3	O
(	O
T	O
(	O
3	O
)	O
)	O
approximately	O
12	O
months	O
post	O
-	O
PCI	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Is	O
psychotherapy	O
more	O
effective	O
when	O
therapists	O
disclose	O
information	B-I
about	I-I
themselves	I-I
?	O
.	O

METHODS	O
:	O
To	O
test	O
these	O
competing	O
positions	O
,	O
therapists	B-P
at	I-P
a	I-P
university	I-P
counseling	I-P
center	I-P
were	O
instructed	O
to	O
increase	O
the	B-I
number	I-I
of	I-I
self	I-I
-	I-I
disclosures	I-I
they	O
made	O
during	O
treatment	O
of	O
one	O
client	O
and	O
refrain	O
from	O
making	O
self	B-I
-	I-I
disclosures	I-I
during	O
treatment	O
of	O
another	O
client	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
a	B-I
new	I-I
computer	I-I
intervention	I-I
to	O
teach	O
people	B-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
to	O
recognize	O
and	O
predict	O
emotions	O
in	O
others	O
.	O

METHODS	O
:	O
Two	B-P
groups	I-P
of	I-P
11	I-P
children	I-P
(	I-P
age	I-P
12	I-P
-	I-P
18	I-P
)	I-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
at	I-P
two	I-P
special	I-P
schools	I-P
participated	O
:	O
one	O
group	O
used	O
the	B-I
computer	I-I
program	I-I
for	O
10	O
half	O
-	O
hour	O
sessions	O
over	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetic	O
study	O
of	O
human	B-I
immunodeficiency	I-I
virus	I-I
protease	I-I
inhibitors	I-I
used	O
in	O
combination	O
with	O
amprenavir	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Prognostic	O
significance	O
of	O
the	B-I
dobutamine	I-I
echocardiography	I-I
test	I-I
in	O
idiopathic	O
dilated	O
cardiomyopathy	O
.	O

METHODS	O
:	O
From	O
February	O
1	O
,	O
1997	O
,	O
to	O
October	O
1	O
,	O
1999	O
,	O
186	B-P
patients	I-P
(	I-P
131	I-P
men	I-P
and	I-P
55	I-P
women	I-P
,	I-P
mean	I-P
age	I-P
56	I-P
+	I-P
/	I-P
-	I-P
12	I-P
years	I-P
)	I-P
with	I-P
IDC	I-P
,	I-P
ejection	I-P
fraction	I-P
<	I-P
35	I-P
%	I-P
,	I-P
and	I-P
angiographically	I-P
normal	I-P
coronary	I-P
arteries	I-P
were	O
studied	O
by	O
high	B-I
-	I-I
dose	I-I
(	I-I
up	I-I
to	I-I
40	I-I
micro	I-I
/	I-I
kg	I-I
/	I-I
min	I-I
)	I-I
dobutamine	I-I
echo	I-I
in	O
6	O
centers	O
,	O
all	O
quality	O
controlled	O
for	O
stress	O
echo	O
reading	O
.	O

-DOCSTART-	O

Title	O
:	O
Pacifier	B-I
as	O
a	O
risk	O
factor	O
for	O
acute	O
otitis	O
media	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
oxolamine	B-I
on	O
cough	O
sensitivity	O
in	O
COPD	B-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
application	O
of	O
irradiated	B-I
drug	I-I
-	I-I
containing	I-I
porcine	I-I
-	I-I
cornea	I-I
to	O
patients	B-P
with	I-P
ocular	I-P
burns	I-P
]	O
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
five	I-P
cases	I-P
of	I-P
patients	I-P
with	I-P
ocular	I-P
burns	I-P
(	I-P
in	I-P
88	I-P
eyes	I-P
)	I-P
were	O
randomly	O
divided	O
into	O
treatment	O
and	O
control	O
groups	O
.	O

Thirty	O
cases	O
in	O
treatment	O
group	O
with	O
49	O
eyes	O
were	O
transplanted	O
with	O
irradiated	B-I
drug	I-I
-	I-I
containing	I-I
(	I-I
ofloxacin	I-I
,	I-I
acetyl	I-I
cysteine	I-I
and	I-I
reduced	I-I
glutathione	I-I
)	I-I
porcine	I-I
-	I-I
cornea	I-I
.	O

25	O
cases	O
in	O
control	O
group	O
with	O
39	O
eyes	O
were	O
treated	O
with	O
routine	B-C
program	I-C
.	O

-DOCSTART-	O

Title	O
:	O
The	O
interaction	O
between	O
propofol	B-I
and	O
clonidine	B-I
for	O
loss	O
of	O
consciousness	O
.	O

Clonidine	O
premedication	O
reduces	O
the	O
intraoperative	O
requirement	O
for	O
opioids	O
and	O
volatile	O
anesthetics	O
.	O

Clonidine	O
also	O
reduces	O
the	O
induction	O
dose	O
of	O
IV	O
anesthetics	O
.	O

There	O
is	O
no	O
information	O
,	O
however	O
,	O
regarding	O
the	O
effect	O
of	O
oral	O
clonidine	O
premedication	O
on	O
the	O
propofol	O
blood	O
concentrations	O
required	O
for	O
loss	O
of	O
consciousness	O
,	O
and	O
the	O
interaction	O
between	O
propofol	O
and	O
clonidine	O
.	O

We	O
randomly	O
administered	O
target	O
effect	O
-	O
site	O
concentrations	O
of	O
propofol	O
ranging	O
from	O
0	O
.	O
5	O
to	O
5	O
.	O

0	O
microg	O
/	O
mL	O
by	O
using	O
computer	O
-	O
assisted	O
target	O
-	O
controlled	O
infusion	O
to	O
3	O
groups	O
of	O
healthy	O
male	O
patients	O
:	O
Control	O
(	O
n	O
=	O
35	O
)	O
,	O
2	O
.	O
5	O
microg	O
/	O
kg	O
Clonidine	O
(	O
n	O
=	O
36	O
)	O
,	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
Clonidine	O
(	O
n	O
=	O
36	O
)	O
groups	O
.	O

Nothing	O
was	O
administered	O
to	O
the	O
Control	O
group	O
.	O

Clonidine	O
(	O
2	O
.	O
5	O
or	O
5	O
.	O
0	O
microg	O
/	O
kg	O
)	O
was	O
administered	O
orally	O
90	O
min	O
before	O
the	O
induction	O
of	O
anesthesia	O
in	O
the	O
Clonidine	O
groups	O
.	O

After	O
equilibration	O
between	O
the	O
blood	O
and	O
effect	O
-	O
site	O
for	O
15	O
min	O
,	O
a	O
verbal	O
command	O
to	O
open	O
their	O
eyes	O
was	O
given	O
two	O
times	O
to	O
the	O
patients	O
.	O

Arterial	O
blood	O
samples	O
for	O
analysis	O
of	O
the	O
serum	O
propofol	O
and	O
clonidine	O
concentrations	O
were	O
taken	O
immediately	O
before	O
verbal	O
commands	O
were	O
given	O
.	O

Measured	O
serum	O
propofol	O
concentrations	O
in	O
equilibrium	O
with	O
the	O
effect	O
-	O
site	O
at	O
which	O
50	O
%	O
of	O
the	O
patients	O
did	O
not	O
respond	O
to	O
verbal	O
commands	O
(	O
EC50	O
for	O
loss	O
of	O
consciousness	O
)	O
were	O
determined	O
by	O
logistic	O
regression	O
.	O

The	O
EC50	O
+	O
/	O
-	O
SE	O
values	O
in	O
the	O
Control	O
,	O
2	O
.	O
5	O
microg	O
/	O
kg	O
Clonidine	O
,	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
Clonidine	O
groups	O
were	O
2	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
18	O
,	O
1	O
.	O
31	O
+	O
/	O
-	O
0	O
.	O
12	O
,	O
and	O
0	O
.	O
91	O
+	O
/	O
-	O
0	O
.	O
13	O
microg	O
/	O
mL	O
,	O
respectively	O
.	O

The	O
EC50	O
in	O
the	O
2	O
.	O
5	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
clonidine	O
groups	O
was	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
Control	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
use	O
of	O
a	O
response	O
surface	O
modeling	O
analysis	O
indicated	O
that	O
there	O
was	O
an	O
additive	O
interaction	O
between	O
measured	O
arterial	O
propofol	O
and	O
clonidine	O
concentrations	O
in	O
relation	O
to	O
loss	O
of	O
consciousness	O
.	O

These	O
results	O
indicate	O
that	O
propofol	O
and	O
clonidine	O
act	O
additively	O
for	O
loss	O
of	O
consciousness	O
.	O

-DOCSTART-	O

Title	O
:	O
Short	B-I
-	I-I
term	I-I
intravenous	I-I
antibiotic	I-I
treatment	I-I
of	O
acute	O
hematogenous	O
bone	O
and	O
joint	O
infection	O
in	O
children	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

METHODS	O
:	O
The	O
treatment	O
outcome	O
was	O
measured	O
through	O
a	B-O
detailed	I-O
scoring	I-O
system	I-O
that	O
included	O
the	O
ability	O
to	O
eradicate	O
infection	O
,	O
the	O
functional	O
status	O
of	O
the	O
limb	O
,	O
and	O
the	O
radiographic	O
appearance	O
of	O
the	O
bone	O
and	O
joint	O
.	O

-DOCSTART-	O

Title	O
:	O
Oat	B-I
ingestion	I-I
reduces	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
in	O
patients	B-P
with	I-P
mild	I-P
or	I-P
borderline	I-P
hypertension	I-P
:	O
a	O
pilot	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
controlled	O
,	O
parallel	O
-	O
group	O
pilot	O
study	O
designed	O
to	O
compare	O
an	B-I
oat	I-I
cereal	I-I
group	O
(	O
standardized	O
to	O
5	O
.	O
52	O
g	O
/	O
day	O
beta	O
-	O
glucan	O
)	O
to	O
a	B-C
low	I-C
-	I-C
fiber	I-C
cereal	I-C
control	O
group	O
(	O
less	O
than	O
1	O
.	O
0	O
g	O
/	O
day	O
total	O
fiber	O
)	O
over	O
6	O
weeks	O
.	O

A	B-P
total	I-P
of	I-P
18	I-P
hypertensive	I-P
and	I-P
hyperinsulinemic	I-P
(	I-P
=	I-P
10	I-P
U	I-P
/	I-P
mL	I-P
or	I-P
more	I-P
)	I-P
men	I-P
and	I-P
women	I-P
completed	O
the	O
trial	O
.	O

Primary	O
study	O
outcomes	O
were	O
changes	O
in	O
systolic	B-O
blood	I-O
pressure	I-O
(	I-O
SBP	I-O
)	I-O
and	O
diastolic	B-O
blood	I-O
pressure	I-O
(	I-O
DBP	I-O
)	I-O
.	O

Secondary	O
outcomes	O
included	O
blood	B-O
lipid	I-O
,	O
fasting	B-O
glucose	I-O
,	O
and	O
insulin	B-O
levels	I-O
and	O
side	B-O
effects	I-O
related	O
to	O
elevated	B-O
blood	I-O
pressure	I-O
and	O
increased	B-O
dietary	I-O
fiber	I-O
intake	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Prolonged	B-I
GnRH	I-I
agonist	I-I
and	O
add	B-I
-	I-I
back	I-I
therapy	I-I
for	O
symptomatic	O
endometriosis	O
:	O
long	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
post	O
-	O
treatment	O
follow	O
-	O
up	O
analysis	O
of	O
a	O
randomized	O
,	O
double	O
-	O
masked	O
,	O
placebo	O
-	O
controlled	O
52	O
-	O
week	O
trial	O
.	O

All	O
patients	O
had	O
received	O
monthly	O
leuprolide	O
acetate	O
and	O
were	O
randomized	O
to	O
one	O
of	O
four	O
groups	O
:	O
A	O
-	O
daily	B-C
placebo	I-C
;	O
B	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
;	O
C	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
and	O
conjugated	B-I
equine	I-I
estrogens	I-I
0	O
.	O
625	O
mg	O
;	O
and	O
D	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
and	O
conjugated	B-I
equine	I-I
estrogens	I-I
1	O
.	O
25	O
mg	O
.	O

Of	O
201	B-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
initial	I-P
trial	I-P
,	I-P
123	I-P
completed	I-P
at	I-P
least	I-P
280	I-P
days	I-P
of	I-P
therapy	I-P
and	I-P
entered	I-P
the	I-P
follow	I-P
-	I-P
up	I-P
period	I-P
.	O

Physical	B-O
findings	I-O
and	O
symptoms	B-O
were	O
quantified	O
,	O
and	O
lumbar	B-O
spine	I-O
bone	I-O
mineral	I-O
density	I-O
was	O
determined	O
at	O
intervals	O
for	O
up	O
to	O
12	O
and	O
24	O
months	O
post	O
-	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Lack	O
of	O
benefit	O
of	O
an	B-I
active	I-I
pectoral	I-I
pulse	I-I
generator	I-I
on	O
atrial	O
defibrillation	O
thresholds	O
.	O

-DOCSTART-	O

Title	O
:	O
Do	O
colonic	O
short	O
-	O
chain	O
fatty	O
acids	O
contribute	O
to	O
the	O
long	O
-	O
term	O
adaptation	O
of	O
blood	O
lipids	O
in	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
consuming	O
a	B-I
high	I-I
-	I-I
fiber	I-I
diet	I-I
?	O
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
(	I-P
n	I-P
=	I-P
62	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
approximately	O
10	O
%	O
of	O
energy	O
from	O
low	B-I
-	I-I
fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
LF	I-I
diet	I-I
)	I-I
,	O
high	B-I
-	I-I
fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
HF	I-I
diet	I-I
)	I-I
,	O
or	O
monounsaturated	B-I
fatty	I-I
acids	I-I
(	I-I
MUFA	I-I
diet	I-I
)	I-I
for	O
6	O
mo	O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
different	O
platelet	B-I
glycoprotein	I-I
IIb	I-I
/	I-I
IIIa	I-I
receptor	I-I
inhibitors	I-I
among	O
diabetic	B-P
patients	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
:	O
:	O
Do	O
Tirofiban	B-I
and	O
ReoPro	B-I
Give	O
Similar	O
Efficacy	O
Outcomes	O
Trial	O
(	O
TARGET	O
)	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Superior	O
survival	O
with	O
capecitabine	B-I
plus	I-I
docetaxel	I-I
combination	I-I
therapy	I-I
in	O
anthracycline	B-P
-	I-P
pretreated	I-P
patients	I-P
with	I-P
advanced	I-P
breast	I-P
cancer	I-P
:	O
phase	O
III	O
trial	O
results	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
to	O
21	B-I
-	I-I
day	I-I
cycles	I-I
of	I-I
oral	I-I
capecitabine	I-I
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
on	O
days	O
1	O
to	O
14	O
plus	O
docetaxel	B-I
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
255	O
)	O
or	O
to	O
docetaxel	B-I
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
256	O
)	O
.	O

